Access to Defibrotide (US)
Healthcare professionals in the U.S. may be able to obtain Defibrotide for the treatment of patients with veno-occlusive disease through a Gentium sponsored Expanded Access, Treatment IND Protocol, Protocol 2006-05.
Details of the protocol including a list of centers in the United States active in the study can be found on clinicaltrials.gov, NCT00628498".
Institutions/Investigators who are interested in this study, please contact Ms. Robin Hume (rhume@gentium.it)
Access to Defibrotide (Ex-US)
Healthcare professionals outside of the U.S. and Italy may be able to obtain Defibrotide via a named patient use program by contacting IDIS at +44 (0) 1932 824 100 or by sending an e-mail to globalsales@idispharma.com.
Healthcare professionals in Australia and New Zealand may be able to obtain Defibrotide via a named patient use program by contacting LINK Medical Products Customer Service Department at +61 (0) 28 401 9777 or by sending an e-mail to customerservice@linkgroup.com.au
Healthcare professionals in Latin America may be able to obtain Defibrotide via a named patient use program by contacting Masters Pharmaceuticals Limited at +44 208 327 0900 or by sending an e-mail to info@mastersglobal.com
Healthcare professionals in Turkey may be able to obtain Defibrotide via a named patient use program by contacting GEN ILAC – Pharm. Nihan Mahanoglu at +90 312 219 62 19 (159) or by sending an e-mail to n.mahanoglu@genilac.com
Healthcare professionals in Israel and Palestinian Authority may be able to obtain Defibrotide via a named patient use program by contacting Medison Pharma Ltd.– Mrs.Inbal Cohen-Peeri at +972 3 925 0270 – fax +972 3 921 9824 or by sending an e-mail to inbal@medison.co.il
Healthcare professionals in South Korea may be able to obtain Defibrotide via a named patient use program by contacting BL&H Co, Ltd.– Business Development Department at +82 2 3281 9072 – fax +82 2 3281 9081 or by sending an e-mail to blnh@blnh.co.kr